- Home
- AZUL vs OBIO Comparison
AZUL vs OBIO Comparison
Compare AZUL & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZUL
- OBIO
- Stock Information
- Founded
- AZUL 2008
- OBIO 2017
- Country
- AZUL Brazil
- OBIO United States
- Employees
- AZUL N/A
- OBIO N/A
- Industry
- AZUL Air Freight/Delivery Services
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- AZUL Consumer Discretionary
- OBIO Health Care
- Exchange
- AZUL Nasdaq
- OBIO Nasdaq
- Market Cap
- AZUL 207.6M
- OBIO 198.2M
- IPO Year
- AZUL 2017
- OBIO N/A
- Fundamental
- Price
- AZUL $1.82
- OBIO $4.72
- Analyst Decision
- AZUL Buy
- OBIO Strong Buy
- Analyst Count
- AZUL 9
- OBIO 4
- Target Price
- AZUL $5.35
- OBIO $16.25
- AVG Volume (30 Days)
- AZUL 1.4M
- OBIO 50.3K
- Earning Date
- AZUL 02-24-2025
- OBIO 03-26-2025
- Dividend Yield
- AZUL N/A
- OBIO N/A
- EPS Growth
- AZUL N/A
- OBIO N/A
- EPS
- AZUL N/A
- OBIO N/A
- Revenue
- AZUL $3,468,415,494.00
- OBIO $2,647,000.00
- Revenue This Year
- AZUL N/A
- OBIO $22.61
- Revenue Next Year
- AZUL $14.55
- OBIO $16.64
- P/E Ratio
- AZUL N/A
- OBIO N/A
- Revenue Growth
- AZUL 4.33
- OBIO N/A
- 52 Week Low
- AZUL $1.57
- OBIO $3.96
- 52 Week High
- AZUL $8.73
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- AZUL 39.81
- OBIO 38.59
- Support Level
- AZUL $1.86
- OBIO $5.20
- Resistance Level
- AZUL $2.09
- OBIO $5.98
- Average True Range (ATR)
- AZUL 0.12
- OBIO 0.42
- MACD
- AZUL -0.03
- OBIO -0.07
- Stochastic Oscillator
- AZUL 13.08
- OBIO 2.70
About AZUL Azul S.A. (each representing three preferred shares)
Azul SA is involved in the operation of regular and non-regular airline passenger services, cargo or mail, passenger charter, provision of maintenance and hangarage services for aircraft, engines, parts and pieces, aircraft acquisition and lease, development of frequent-flyer programs, development of related activities and equity holding in other companies. The Company considers that it has a single reportable segment which is air transport.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.